{"id":"W4296532460","doi":"10.1016/s2152-2650(22)00702-9","title":"Oral Abstract: HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Ottawa Hospital","funders":"","keywords":"Classical Hodgkin lymphoma; Refractory (planetary science); Open label; Medicine; Internal medicine; Oncology; Phases of clinical research; Multicenter study; Lymphoma; Gastroenterology; Adverse effect; Clinical trial; Hodgkin lymphoma; Biology; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001043254,0.0008843502,0.001325879,0.0003562431,0.0004025936,0.001254166,0.0008858226,0.001341458,0.02925543],"category_scores_gemma":[0.0007416716,0.000344667,0.0009083577,0.000284419,0.0004105805,0.0006987978,0.0003065188,0.002415096,0.004320736],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006376669,"about_ca_system_score_gemma":0.0007532545,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000857343,"about_ca_topic_score_gemma":0.00234052,"domain_scores_codex":[0.999764,0.00007963344,0.00001286069,0.00004112518,0.0000549734,0.00004742833],"domain_scores_gemma":[0.9996004,0.00006838918,0.0001030946,0.00002444244,0.00003548589,0.0001682163],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4850034,0.01783868,0.004914965,0.002267307,0.002326976,0.0003988766,0.0001789161,0.001386544,0.04116254,0.0008424325,0.08573179,0.3579476],"study_design_scores_gemma":[0.6900645,0.198753,0.03582572,0.0003096436,0.002589588,0.0006626415,0.0001191983,0.001739974,0.01038127,0.0005250847,0.05890563,0.0001236498],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8932282,0.02616599,0.002998706,0.007613015,0.003082921,0.005121156,0.02549184,0.001695355,0.03460288],"genre_scores_gemma":[0.925886,0.008282493,0.003868581,0.006005671,0.00169703,0.001761621,0.01281293,0.0002403843,0.03944527],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02925543,"threshold_uncertainty_score":0.09786916,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06725159472618122,"score_gpt":0.3975938157853207,"score_spread":0.3303422210591395,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}